CRISPR Therapeutics Crecimiento futuro
Future controles de criterios 2/6
CRISPR Therapeutics se prevé un crecimiento anual de los beneficios y los ingresos de 46.5% y 46.5% respectivamente. Se prevé que el BPA sea de grow en 44.8% al año. Se prevé que la rentabilidad de los fondos propios sea de 13.8% en 3 años.
Información clave
37.6%
Tasa de crecimiento de los beneficios
37.5%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 20.7% |
| Tasa de crecimiento de los ingresos | 37.6% |
| Rentabilidad financiera futura | 9.5% |
| Cobertura de analistas | Good |
| Última actualización | 18 Apr 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Apr 16
Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape
Mar 26There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump
Feb 22Crispr Therapeutics: Cautiously Optimistic
Feb 22Crispr Therapeutics: Investors Bet Against Casgevy Uptake
Feb 01Crispr Therapeutics: Commercial Validation Is The Next Step
Jan 18Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry
Jan 11CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing
Dec 25CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Nov 02A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Oct 05CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price
Sep 14We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate
Jul 24Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Jun 28CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Apr 02CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 06Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth
Dec 08CRISPR CAR T cell therapy for skin/blood cancer gets FDA regenerative medicine tag
Sep 28Crispr: Elucidating And Forecasting Key Developments
Sep 21Crispr Therapeutics: Nearing Harvest Season
Sep 08Crispr Therapeutics: Unlikely To Fall To May Lows, But Not The Time To Buy Yet (Technical Analysis)
Aug 25News Flash: Analysts Just Made A Noticeable Upgrade To Their CRISPR Therapeutics AG (NASDAQ:CRSP) Forecasts
Aug 09CRISPR Therapeutics GAAP EPS of -$2.40 misses by $0.19, revenue of $0.16M misses by $2.04M
Aug 08Crispr Therapeutics' Continued Progress Warrants A Buy
Jul 25Crispr Therapeutics: Innovation Day Showcases Upside Opportunities In Short And Long Term
Jun 23Crispr Therapeutics: Progress, Risk, And Reward
Apr 27The Commercial Potential Of Crispr In Light Of Patent Challenges
Mar 22Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 930 | -180 | -234 | -31 | 14 |
| 12/31/2025 | 404 | -381 | -314 | -261 | 23 |
| 12/31/2024 | 121 | -454 | -284 | -186 | 26 |
| 12/31/2023 | 371 | -154 | -272 | -260 | N/A |
| 9/30/2023 | 170 | -354 | -295 | -278 | N/A |
| 6/30/2023 | 170 | -416 | -363 | -343 | N/A |
| 3/31/2023 | 100 | -524 | -377 | -352 | N/A |
| 12/31/2022 | 1 | -650 | -533 | -496 | N/A |
| 9/30/2022 | 14 | -681 | -509 | -468 | N/A |
| 6/30/2022 | 15 | -633 | -516 | -445 | N/A |
| 3/31/2022 | 915 | 312 | 414 | 504 | N/A |
| 12/31/2021 | 915 | 378 | 457 | 539 | N/A |
| 9/30/2021 | 902 | 412 | 465 | 544 | N/A |
| 6/30/2021 | 902 | 447 | 502 | 549 | N/A |
| 3/31/2021 | 1 | -392 | -309 | -287 | N/A |
| 12/31/2020 | 1 | -349 | -257 | -238 | N/A |
| 9/30/2020 | 77 | -211 | -167 | -154 | N/A |
| 6/30/2020 | 289 | 20 | 45 | 55 | N/A |
| 3/31/2020 | 289 | 46 | 40 | 48 | N/A |
| 12/31/2019 | 290 | 67 | 50 | 57 | N/A |
| 9/30/2019 | 213 | -11 | 18 | 25 | N/A |
| 6/30/2019 | 1 | -200 | -133 | -128 | N/A |
| 3/31/2019 | 2 | -185 | -121 | -117 | N/A |
| 12/31/2018 | 3 | -165 | -99 | -96 | N/A |
| 9/30/2018 | 35 | -117 | -85 | -83 | N/A |
| 6/30/2018 | 37 | -91 | -83 | -79 | N/A |
| 3/31/2018 | 40 | -75 | -74 | -69 | N/A |
| 12/31/2017 | 41 | -68 | -78 | -70 | N/A |
| 9/30/2017 | 11 | -51 | N/A | -75 | N/A |
| 6/30/2017 | 10 | -41 | N/A | -71 | N/A |
| 3/31/2017 | 7 | -36 | N/A | -69 | N/A |
| 12/31/2016 | 5 | -23 | N/A | -53 | N/A |
| 9/30/2016 | 3 | -53 | N/A | 33 | N/A |
| 6/30/2016 | 2 | -44 | N/A | 40 | N/A |
| 3/31/2016 | 1 | -31 | N/A | 51 | N/A |
| 12/31/2015 | 0 | -26 | N/A | 59 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: CRSP se prevé que siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: CRSP se prevé que siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: CRSP se prevé que siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: CRSPSe prevé que los ingresos de la empresa (46.5% al año) crezcan más deprisa que los del mercado US (8.1% al año).
Ingresos de alto crecimiento: CRSPSe prevé que los ingresos de la empresa (46.5% al año) crezcan más deprisa que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: CRSPSe prevé que la Rentabilidad de los fondos propios de la empresa sea baja dentro de 3 años (13.8%).